PSMA6 and benign prostatic hyperplasia: Tamsulosin and alfuzosin (alpha-1 blockers), in conjunction with traditional 5α-reductase inhibitors (finasteride and dutasteride), have been the mainstay of pharmacotherapy for BPH over the years [8].